MitOxyVit: Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524709-34-00

Enrollment

Registered

2026-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

Mean percentage of change from baseline (CFB) of VASI at week 24.

Detailed description

1. Mean percentage of change from baseline (CFB) of VASI at week 12, 2. VSAS between baseline and each visit, 3. VNS between baseline and each visit, 4. Frequency and severity of adverse events collection

Interventions

DRUGOXYGENE MEDICINAL LINDE HEALTHCARE 200 bar

DRUGgaz pour inhalation

DRUGen bouteille

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean percentage of change from baseline (CFB) of VASI at week 24.	—

Secondary

Measure	Time frame
1. Mean percentage of change from baseline (CFB) of VASI at week 12, 2. VSAS between baseline and each visit, 3. VNS between baseline and each visit, 4. Frequency and severity of adverse events collection	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 25, 2026